TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38555865

Group type: EXPERIMENTAL
Intervention: Intensified cooperation between GP, care manager, and rehabilitation coordinator plus a person-centred dialogue meeting with employer within 3 months.
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual care manager contact (control group).
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Intensified cooperation and dialogue meeting (intervention group).
Number of subjects: 258
Study: 38555923

Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR T-cell infusion
Number of subjects: 21
Study: 38556413

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionated radiotherapy combined with a radiosensitizer (intravenous or oral drug) administered 5 days a week for 4 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionated radiotherapy combined with a radiosensitizer (intravenous or oral drug).
Number of subjects: 0
Study: 38556640

Group type: EXPERIMENTAL
Intervention: Water Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38556717

Group type: EXPERIMENTAL
Intervention: Direct sodium removal (DSR) with loop diuretic withdrawal; median time of DSR 4 weeks (IQR 4-6); baseline median 240 mg furosemide equivalents/day withdrawn during DSR.
Number of subjects: 18
Study: 38557264

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 45
Study: 38557285

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 34
Study: 38557315

Group type: EXPERIMENTAL
Intervention: AI-based risk prediction system for graft loss, starting from 3 months after randomization until 24 months after randomization.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Routine post-kidney transplant care (control group).
Number of subjects: 122
Study: 38557430

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus newly initiated oral antidepressant (OAD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antidepressant (OAD) plus placebo nasal spray (PBO)
Number of subjects: 0
Study: 38557591

Group type: EXPERIMENTAL
Intervention: Digital educational intervention focusing on front-of-package warning labels
Number of subjects: 0

Group type: COMPARATOR
Intervention: General nutritional education (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance on reading labels and awareness about ultraprocessed products (Intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-question exam to evaluate theoretical understanding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-hour reminder, survey on food habits and consumption, food preference scale, anthropometric measurements, recording of school lunch choices
Number of subjects: 0
Study: 38557639

Group type: EXPERIMENTAL
Intervention: H56:IC31 (5 mg H56:500 nmol IC31)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 38557684

Group type: EXPERIMENTAL
Intervention: GCS-EM (sum of eye and motor components of the Glasgow Coma Score)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses with different adjustment covariates
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Subgroup analyses by brain injury diagnosis or age
Number of subjects: 1152
Study: 38557692

Group type: EXPERIMENTAL
Intervention: Mobile WACh Empower intervention (tablet-based RH decision-support counseling tool and SMS support during two years of follow-up)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Mobile WACh Empower intervention
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Standard of care FP counseling (control group)
Number of subjects: 3300
Study: 38557775

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel; autologous anti-CD19 chimeric antigen receptor T-cell therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (2-3 cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transplantation in patients who had a response)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 38557809

Group type: EXPERIMENTAL
Intervention: Anti-BTN3A activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: SARS-CoV-2 infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing concentrations of anti-BTN3A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vγ9Vδ2 T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BTN3A upregulation and Vγ9Vδ2 T-cell infiltration
Number of subjects: 0
Study: 38557877

Group type: EXPERIMENTAL
Intervention: HSP-SNAP questionnaire
Number of subjects: 40
Study: 38557950

Group type: EXPERIMENTAL
Intervention: Regenerative Peripheral Nerve Interface (RPNI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuroma excision coupled with intra-muscular transposition and burying
Number of subjects: 0
Study: 38557959

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (TD group)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (TD group)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (HD group)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (HD group)
Number of subjects: 468
Study: 38558106

Group type: EXPERIMENTAL
Intervention: B-cell-targeted CAR T-cell therapy (tisagenlecleucel infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) and IL-15 exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro activated and patient-derived T cells with a bystander phenotype
Number of subjects: 0
Study: 38558248

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 121
Study: 38558247

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard oncological care (SOC)
Number of subjects: 146
Study: 38558265

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy (LFIO)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 35
Study: 38558269

Group type: EXPERIMENTAL
Intervention: Cluster 1 (CL1) with ADIPO-IR = 4.9 ± 2.4 and WC = 96 ± 7 cm
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Cluster 2 (CL2) with ADIPO-IR = 6.5 ± 2.5 and WC = 114 ± 7 cm
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Cluster 3 (CL3) with ADIPO-IR = 15.0 ± 4.7 and WC = 107 ± 8 cm
Number of subjects: 192
Study: 38558321

Group type: EXPERIMENTAL
Intervention: Automated ePRO exercise module intervention
Number of subjects: 180
Study: 38558387

Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Designed physical therapy program (Control)
Number of subjects: 40
Study: 38558411

Group type: EXPERIMENTAL
Intervention: Whole-food blended smoothie as exclusive enteral nutrition (EEN)
Number of subjects: 10
Study: 38558478

Group type: EXPERIMENTAL
Intervention: Plasma levels of CGRP in individuals with rosacea
Number of subjects: 123

Group type: COMPARATOR
Intervention: Plasma levels of CGRP in healthy controls
Number of subjects: 123
Study: 38558761

Group type: EXPERIMENTAL
Intervention: Xpert Bladder Cancer Monitor
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck
Number of subjects: 240

Group type: COMPARATOR
Intervention: Frequent cystoscopy
Number of subjects: 240
Study: 38558767

Group type: EXPERIMENTAL
Intervention: Videoendoscopic inguinal lymphadenectomy (VEILND)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Open inguinal lymphadenectomy (OILND)
Number of subjects: 14
Study: 38558910

Group type: EXPERIMENTAL
Intervention: Moderate continuous training (MCT) at 60-70% of peak heart rate (HR)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIIT) at 90-95% peak HR
Number of subjects: 231

Group type: COMPARATOR
Intervention: Recommendation of regular exercise (RRE) according to guidelines
Number of subjects: 231
Study: 38558946

Group type: EXPERIMENTAL
Intervention: Telephone Follow-Up (TFU)
Number of subjects: 0
Study: 38558955

Group type: EXPERIMENTAL
Intervention: Face-to-Face (F2F) Creative Movement Intervention
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Telehealth (TH) Creative Movement Intervention
Number of subjects: 15
Study: 38559210

Group type: EXPERIMENTAL
Intervention: Exercise (home-based, individually tailored, moderate intensity, progressive walking and resistance training)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active control (nutrition education)
Number of subjects: 19
Study: 38559225

Group type: EXPERIMENTAL
Intervention: Partner-assisted intervention (n=115)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Participant-only intervention (n=116)
Number of subjects: 231
Study: 38559259

Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Mood management and self-efficacy strategies
Number of subjects: 449
Study: 38559284

Group type: EXPERIMENTAL
Intervention: Intravenous administration of umbilical cord lining stem cells (ULSCs)
Number of subjects: 18
Study: 38559338

Group type: EXPERIMENTAL
Intervention: Ultra-low-temperature cryoablation (ULTC)
Number of subjects: 18
Study: 38559493

Group type: EXPERIMENTAL
Intervention: Food allergies
Number of subjects: 1680
Study: 38559746

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38559796

Group type: EXPERIMENTAL
Intervention: Single cDMARD plus anti-TNF therapy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Multiple cDMARDs
Number of subjects: 207
Study: 38559896

Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Focus groups for children who survived pediatric ALL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pilot trial of FBT
Number of subjects: 20
Study: 38560191

Group type: EXPERIMENTAL
Intervention: Structural abnormalities on chest CT (Emphysema, BE, TDL)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Emphysema
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Bronchiectasis (BE)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Tree-in-bud (TDL)
Number of subjects: 237
Study: 38560406

Group type: EXPERIMENTAL
Intervention: True PC-TEAS
Number of subjects: 188

Group type: COMPARATOR
Intervention: Sham PC-TEAS
Number of subjects: 188
Study: 38560407

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (sc IFN β-1a) 44 μg once weekly (qw)
Number of subjects: 494
Study: 38560416

Group type: EXPERIMENTAL
Intervention: suboptimal peak inspiratory flow (sPIF) (<60 L/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: optimal peak inspiratory flow (oPIF) (≥60 L/min)
Number of subjects: 0
Study: 38560556

Group type: EXPERIMENTAL
Intervention: Coronary atheroma burden (AB), percent diameter stenosis (PDS), tapering reference diameter Z score (RDZ)
Number of subjects: 51
Study: 38560604

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 38560639

Group type: EXPERIMENTAL
Intervention: Permanent polymer zotarolimus-eluting stent with 12 months DAPT for troponin-positive patients
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: Permanent polymer zotarolimus-eluting stent with 1 month DAPT for troponin-negative patients
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stent with 12 months DAPT for troponin-positive patients
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stent with 1 month DAPT for troponin-negative patients
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: HBR patients
Number of subjects: 1488

Group type: COMPARATOR
Intervention: Non-HBR patients
Number of subjects: 1488
Study: 38560901

Group type: EXPERIMENTAL
Intervention: Prediction model for SMM or worse
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Mayo Clinic risk stratification model
Number of subjects: 1043
Study: 38560960

Group type: EXPERIMENTAL
Intervention: Low-dose amisulpride (100-300 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olanzapine-fluoxetine combination (OFC) (5/10 mg + 20 mg)
Number of subjects: 60
Study: 38561010

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemoradiotherapy
Number of subjects: 804

Group type: COMPARATOR
Intervention: Placebo plus chemoradiotherapy
Number of subjects: 804
Study: 38561341

Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC)
Number of subjects: 10
Study: 38561497

Group type: EXPERIMENTAL
Intervention: Low-dose dengue virus 3 (DENV-3) challenge
Number of subjects: 9
Study: 38561577

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 762
Study: 38561578

Group type: EXPERIMENTAL
Intervention: 1-year supervised exercise program
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) therapy withdrawal
Number of subjects: 372

Group type: COMPARATOR
Intervention: No AI withdrawal
Number of subjects: 372
Study: 38561682

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglyceride-supplemented Ketogenic Diet (MCT-KD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 16
Study: 38561708

Group type: EXPERIMENTAL
Intervention: 10 week physical exercise intervention (PEI) consisting of resistance and endurance exercises
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no PEI)
Number of subjects: 112
Study: 38561727

Group type: EXPERIMENTAL
Intervention: End-of-life care volunteer services
Number of subjects: 5
Study: 38561773

Group type: EXPERIMENTAL
Intervention: Short foot exercise in addition to hip and knee exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hip and knee exercises only (Control)
Number of subjects: 28
Study: 38561817

Group type: EXPERIMENTAL
Intervention: Postoperative mobilization at 6 hours after surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Postoperative mobilization at 24 hours after surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of OI incidence after UKA vs TKA
Number of subjects: 32
Study: 38561815

Group type: EXPERIMENTAL
Intervention: 9-month all-oral short-course regimen containing bedaquiline (BDQ)
Number of subjects: 212

Group type: COMPARATOR
Intervention: 9-month all-oral short-course regimen without bedaquiline (BDQ)
Number of subjects: 212
Study: 38561821

Group type: EXPERIMENTAL
Intervention: Gait training + tSCS (Stim group)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Gait training alone (Control group)
Number of subjects: 8
Study: 38562251

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 162
Study: 38562678

Group type: EXPERIMENTAL
Intervention: Interruptive Clinical Decision Support (CDS)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Non-Interruptive Clinical Decision Support (CDS)
Number of subjects: 561
Study: 38562783

Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg once/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg twice/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg three times/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 38562810

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring reasons for quitting and strategies to help in quit efforts.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring barriers to quitting.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring quit strategies.
Number of subjects: 11
Study: 38562824

Group type: EXPERIMENTAL
Intervention: EPIC-HIV (male-targeted HIV-specific decision support app)
Number of subjects: 13894

Group type: COMPARATOR
Intervention: No EPIC-HIV (control group)
Number of subjects: 13894

Group type: EXPERIMENTAL
Intervention: EPIC-HIV 2
Number of subjects: 13894

Group type: COMPARATOR
Intervention: EPIC-HIV vs No EPIC-HIV
Number of subjects: 13894
Study: 38562833

Group type: EXPERIMENTAL
Intervention: MPER-peptide liposome (500 mcg or 2000 mcg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 38562873

Group type: EXPERIMENTAL
Intervention: Conditional financial incentives for home-based HIV counseling and testing (HBHCT) and linkage to care (R50 food voucher)
Number of subjects: 33878

Group type: COMPARATOR
Intervention: No financial incentives for home-based HIV counseling and testing (HBHCT) and linkage to care
Number of subjects: 33878
Study: 38562875

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS), administered twice daily during ICU stay.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation, administered twice daily during ICU stay.
Number of subjects: 0
Study: 38563058

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment in phase-3 trials (PRIME/NCT04183335 and PRIME2/NCT04202679)
Number of subjects: 311
Study: 38563246

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for NTM-PD
Number of subjects: 411
Study: 38563386

Group type: EXPERIMENTAL
Intervention: Preprocedural γ-glutamyl transferase (GGT) levels
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Higher GGT levels (based on sex-related thresholds)
Number of subjects: 1800
Study: 38563683

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38563697

Group type: EXPERIMENTAL
Intervention: New compressive garment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38563751

Group type: EXPERIMENTAL
Intervention: Albendazole alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole in combination with mebendazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole in combination with pyrantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38563805

Group type: EXPERIMENTAL
Intervention: Palliative Care Social Work Intervention
Number of subjects: 0
Study: 38563835

Group type: EXPERIMENTAL
Intervention: Left atrial appendage ligation plus pulmonary vein isolation
Number of subjects: 610

Group type: COMPARATOR
Intervention: Pulmonary vein isolation alone
Number of subjects: 610
Study: 38563872

Group type: EXPERIMENTAL
Intervention: Tau positron emission tomography (PET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biodistribution study
Number of subjects: 0
Study: 38563881

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT before prednisolone treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT after 8 weeks of prednisolone treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT after short-term prednisolone discontinuation at week 10
Number of subjects: 101
Study: 38564122

Group type: EXPERIMENTAL
Intervention: Hybrid CDT
Number of subjects: 21

Group type: COMPARATOR
Intervention: CDMT
Number of subjects: 21
Study: 38564167

Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM) intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (CR) control group
Number of subjects: 70
Study: 38564220

Group type: EXPERIMENTAL
Intervention: Group 2 (≤1500 IU and ≥10 days)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Group 3 (>1500 IU and <10 days)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Group 4 (>1500 IU and ≥10 days)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Group 1 (≤1500 IU and <10 days)
Number of subjects: 603
Study: 38564221

Group type: EXPERIMENTAL
Intervention: Automated texting program for 30 days postdischarge
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Standard transitional care management telephone call
Number of subjects: 4736
Study: 38564243

Group type: EXPERIMENTAL
Intervention: Contingency management (money for nondrinking days) for at least 30 days followed by a brief motivational interview.
Number of subjects: 57
Study: 38564264

Group type: EXPERIMENTAL
Intervention: Telepalliation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional standard of care program for palliative care
Number of subjects: 0
Study: 38564365

Group type: EXPERIMENTAL
Intervention: High-Dose Isoniazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38564601

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 19
Study: 38564654

Group type: EXPERIMENTAL
Intervention: Verinurad and Allopurinol combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (Allopurinol alone)
Number of subjects: 0
Study: 38564684

Group type: EXPERIMENTAL
Intervention: MTB recommendations from the original review (not disclosed)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Different MTB review groups
Number of subjects: 306
Study: 38564692

Group type: EXPERIMENTAL
Intervention: Active trial follow-up up to 1 year, linkage to the National Death Index (NDI), and obituary searches
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Linkage to the National Death Index (NDI)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Obituary searches
Number of subjects: 1169
Study: 38564700

Group type: EXPERIMENTAL
Intervention: NAC group (mFOLFOX6 or CAPOX)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Upfront surgery group
Number of subjects: 744
Study: 38564986

Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enasidenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDH2-R140 variant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDH2-R172 variant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAS and RTK pathway mutations
Number of subjects: 0
Study: 38565086

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (25 μg every 2 h until Bishop score ≥7, labor, or maximum of 8 doses)
Number of subjects: 104
Study: 38565389

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 218

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 218